Dr. Bob Ulrich is a Managing Director investing
in the Life Sciences sector at Vanguard. Bob is a seasoned
veteran of both the health care industry and venture capital
community, earning prominence as a technologist, operating
executive, CEO, entrepreneur and venture capital investor.
Prior to joining Vanguard Ventures, Bob was
co-founder and President of VanMed, a Vanguard sponsored business
incubator specialized in seed stage medical opportunities.
He played an active role in several VanMed companies, serving
as CEO of five and a Board of Directors member of seven. Bob
was President and CEO of Menlo Care, Inc., a spinout of Raychem,
which was later acquired by Johnson & Johnson. He served
as President and CEO of MedVest, Inc., a medical incubator,
responsible for analyzing the business and technology aspects
of products for investment and acquisition. Bob's career in
the medical industry began at General Electric and continued
at Johnson & Johnson where he was Director of New Technologies.
In this capacity he directed U.S. and international medical
products business development, investments and acquisitions
for therapeutic and diagnostic devices and pharmaceuticals.
His most notable acquisition was that of the Schatz-Palmaz
coronary stent, which has become one of the most successful
medical devices in history.
He earned his Bachelor of Arts degree in Physics
from Claremont McKenna College, and a Master of Science degree
and Ph.D. in Polymer Science and Engineering from the University
of Massachusetts.
Bob is a member of the Board of Directors for
HemoSense,
Peptimmune,
Percardia,
TissueLink
and Vesalius
Ventures. He is an observer on the Board of Directors
for CryoCor,
BioSeek,
and Sontra.
Administrative assistant:
Pamela Jones
pjones@vanguardventures.com
713-877-1662
< Back to Team Page
about vanguard
| team | portfolio
| for entrepreneurs
| news | contact
us
Copyright © 2002 Vanguard Ventures
|
